Previous reports have demonstrated that ABCB1 and ABCG2 are capable of effluxing small molecule inhibitors of receptor tyrosine kinases (RTKs) such as sunitinib [20,21] and imatinib [22,23,24,25] out of cancer cells. Here, ABCG2 is linked to cancer.